Verismo Therapeutics
Biotechnology, 3675 Market St, Philadelphia, Pennsylvania, 19104, United States, 11-50 Employees
Phone Number: 21********
Who is VERISMO THERAPEUTICS
Verismo Therapeutics is pioneering the development of novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer, especially non-hematologic malig...
Read More
-
Headquarters: 3675 Market St, Philadelphia, Pennsylvania, 19104, United States
-
Date Founded: 2020
-
Employees: 11-50
-
Revenue: Under $1 Million
-
Active Tech Stack: See technologies
-
CEO:
Bryan Kim
Email
Phone
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from VERISMO THERAPEUTICS
Verismo Therapeutics Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Verismo Therapeutics
Answer: Verismo Therapeutics's headquarters are located at 3675 Market St, Philadelphia, Pennsylvania, 19104, United States
Answer: Verismo Therapeutics's phone number is 21********
Answer: Verismo Therapeutics's official website is https://verismotherapeutics.com
Answer: Verismo Therapeutics's revenue is Under $1 Million
Answer: Verismo Therapeutics's SIC: 2836
Answer: Verismo Therapeutics's NAICS: 541714
Answer: Verismo Therapeutics has 11-50 employees
Answer: Verismo Therapeutics is in Biotechnology
Answer: Verismo Therapeutics contact info: Phone number: 21******** Website: https://verismotherapeutics.com
Answer: Verismo Therapeutics is pioneering the development of novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer, especially non-hematologic malignancies with few effective therapeutic options. Verismo Therapeutics core technology is built upon CARs that are uniquely engineered to more realistically reflect the natural multichain design of killer immunoglobulin-like receptors (KIRs), an important family of immunologic receptors used by T cells and NK cells. Preclinical studies show that SynKIRTM-T cells, created by introducing these KIR-based CARs (KIR-CARs) into T cells, more effectively eliminate aggressive tumors in vivo when compared with T cells bearing traditional 2nd generation CAR designs found in current FDA approved CAR-T cell therapies.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month